Daicel (FRA:9DC) Other Stockholders Equity: €549 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9DC Daicel Corp FRA:9DC
84 GF Score
Price €7.90
GF Value €8.08
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Daicel Other Stockholders Equity?

Daicel FRA:9DC +3.27% 84 Other Stockholders Equity is €549 Mil as of Mar. 2026. GuruFocus rates FRA:9DC with a GF Score™ of 84/100 and a GF Value™ of €8.08 (Fairly Valued). The stock has 8 warning signs investors should review.

Daicel's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €549 Mil.

Daicel's quarterly Other Stockholders Equity declined from Sep. 2025 (€544 Mil) to Dec. 2025 (€539 Mil) but then increased from Dec. 2025 (€539 Mil) to Mar. 2026 (€549 Mil).

Daicel's annual Other Stockholders Equity declined from Mar. 2024 (€647 Mil) to Mar. 2025 (€535 Mil) but then increased from Mar. 2025 (€535 Mil) to Mar. 2026 (€549 Mil).

Daicel Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Daicel's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daicel Other Stockholders Equity Chart

Daicel Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 515.48 489.05 647.23 534.67 549.45

Daicel Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 534.67 523.11 544.06 539.29 549.45
FRA:9DC
84GF Score
Daicel Corp FRA:9DC
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daicel Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €549 Mil mean?
Daicel (FRA:9DC) has a Other Stockholders Equity of €549 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Daicel and its competitors.
Is Daicel's Other Stockholders Equity too high?
Daicel's current Other Stockholders Equity is €549 Mil. Overall, Daicel has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daicel's Other Stockholders Equity compare to LIN and SHW?
Daicel's Other Stockholders Equity of €549 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Chemicals company?
A good Other Stockholders Equity depends on the Chemicals industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Daicel and its competitors. Daicel's current Other Stockholders Equity is €549 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daicel stock overvalued right now?
Based on GuruFocus' analysis, Daicel (FRA:9DC) is currently considered Fairly Valued. The stock's GF Value™ is €8.08, compared to a current price of €7.90 — trading 2.2% below its estimated fair value. The current Other Stockholders Equity is €549 Mil. Daicel's overall GF Score™ is 84/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Daicel (FRA:9DC), the current Other Stockholders Equity is €549 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daicel (FRA:9DC) Overvalued in 2026?

Based on GuruFocus' analysis, Daicel stock appears to be undervalued. The current stock price of €7.90 is trading 2.2% below its estimated GF Value™ of €8.08. GuruFocus considers Daicel to be Fairly Valued.

Key valuation signals for FRA:9DC:

  • Other Stockholders Equity: €549 Mil
  • GF Value™: €8.08 vs. price of €7.90 (2.2% below fair value)
  • GF Score™: 84/100 with 8 warning signs

No single metric tells the full story. See the FRA:9DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daicel Business Description

Other Exchanges DACHF:USA4202:Japan
Address 3-1 Ofukacho, Grand Front Osaka Tower B, Kita-ku, Osaka, JPN
Daicel Corp is a Japanese chemical company engaged in engineering plastics, materials, medical health care, safety, smart materials, & other businesses. The company operates through five segments. The Engineering Plastics segment includes polyacetal resins, PET resins, liquid crystal polymers, and related products. The Material segment covers acetic acid, derivatives, acetate tow, cellulose acetate, and cosmetic raw materials. The Medical Health Care segment provides enantiomer separation columns and health food materials. The Safety segment offers inflators for automobile airbags and circuit breakers, while the Smart segment handles caprolactone derivatives, epoxy compounds, semiconductor materials, and functional films. The Others segment includes membranes and transportation warehouses.
84GF Score

Get the complete analysis for FRA:9DC

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€8.08
GF Value